Fig. 1
From: Nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials
Stabilization of Canonical NF-κB-inducing kinase. AML: acute myeloid leukemia, caNIK: canonical nuclear factor κB inducing kinase; Mef2c: myocyte-specific enhancer factor; Dnmt3a: DNA (cytosine-5)-methyltransferase 3A, RNfkbia: nuclear factor that binds to the enhancer element of the Ig kappa light-chain of activated B cells;Tnfaip3: protein induced by TNF-mediated NF-κB activation and has a dual function in regulating NF-κB associated with inflammatory carcinogenesis in many cancer types; TRAF3: TNF receptor-associated factor